The study was carried out in compliance with the Declaration of Helsinki and Good Clinical Practice guidelines; all individuals provided written informed consent before going through any study-related procedures. The study was created by the last two authors and the study sponsor, Celgene, which funded the scholarly study and was involved with data processing, management, statistical analysis, and data interpretation with the investigators together. The initial draft of the manuscript was compiled by the first writer and underwent a critical revision by the last two authors without the professional writing assistance. The rest of the study authors contributed to the revision.Here, we report the outcomes of a phase 3 trial. Methods Study Design and Oversight This double-blind, randomized, placebo-controlled trial was designed by the Jiangsu Provincial Center for Disease Control and Prevention , Sinovac Biotech , the Chinese National Institutes for Food and Drug Control, and the Chinese National Institute for Viral Disease Control and Prevention. Data were collected by investigators at the JSCDC. An unbiased data and basic safety monitoring board consisting of five members monitored updated safety data, evaluated the risk to participants through the trial, and made the final determination of the efficacy end points.